These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15237599)

  • 1. [Ibandronate: keep life in motion].
    Longo F; Mansueto G
    Tumori; 2004; 90(2):9-16. PubMed ID: 15237599
    [No Abstract]   [Full Text] [Related]  

  • 2. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O
    Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
    [No Abstract]   [Full Text] [Related]  

  • 3. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Manikandan R; Mistry R; Philip J; Cornford P
    BJU Int; 2006 Mar; 97(3):653. PubMed ID: 16469048
    [No Abstract]   [Full Text] [Related]  

  • 6. Ask us: Some drugs affect tooth movement.
    Schwartz JE
    Am J Orthod Dentofacial Orthop; 2005 Jun; 127(6):644. PubMed ID: 15968810
    [No Abstract]   [Full Text] [Related]  

  • 7. Zoledronate in the treatment of osteolytic bone metastases.
    Lipton A
    Br J Clin Pract Suppl; 1996 Sep; 87():21; discussion 22. PubMed ID: 8995015
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
    Neville-Webbe Hl; Coleman RE
    Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
    Pecherstorfer M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK
    Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
    [No Abstract]   [Full Text] [Related]  

  • 13. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
    Tomoo T; Suzuki M
    Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
    Rosen L; Harland SJ; Oosterlinck W
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S19-24. PubMed ID: 12562047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
    Nagy Z
    Pathol Oncol Res; 2005; 11(3):186-7. PubMed ID: 16299941
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Parker CC
    J Natl Cancer Inst; 2004 Oct; 96(19):1480; author reply 1480-1. PubMed ID: 15467039
    [No Abstract]   [Full Text] [Related]  

  • 18. New therapeutic agents for the treatment of bone diseases.
    Lipton A
    Expert Opin Biol Ther; 2005 Jun; 5(6):817-32. PubMed ID: 15952912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K; Goa KL
    Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
    Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
    Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.